Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|AKT1 mutant||triple-receptor negative breast cancer||predicted - sensitive||Capivasertib + Paclitaxel||Phase II||Actionable||In a Phase II trial (PAKT), Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (9.3 vs 3.7 months, HR=0.30, p=0.01) compared to placebo in patients with metastatic triple-negative breast cancer harboring PIK3CA, AKT1, and/or PTEN mutations, but not in patients with wile-type PIK3CA, AKT1, and PTEN (5.3 vs 4.4 months, HR=1.13, p=0.61) (PMID: 31841354; NCT02423603).||31841354|